Two new studies support prophylactic, rather than therapeutic, anticoagulation for COVID-19 patients, and case reports provide more information about vaccine-induced immune thrombotic thrombocytopenia.
Beta-blockers after discharge associated with improved outcomes in older patients with heart failure
Ninety-day mortality and readmission rates were significantly lower in Medicare patients who received a beta-blocker after hospital discharge for heart failure with reduced ejection fraction than in those who did not, even if they were 75 years of age and older.
An academic tertiary care hospital in Northern California found that adjusted mean hospital length of stay decreased by 2% and the adjusted odds of 30-day readmission decreased by 14% after implementation of a delirium screening and care pathway for inpatients ages 50 years and older.
A systematic review looked at 60 studies that evaluated four-factor prothrombin complex concentrates, idarucizumab, or andexanet for the treatment of severe or uncontrolled bleeding in patients on a direct oral anticoagulant (DOAC).